Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.31 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487822 | 0.72 | DDB1 (0.33) | — | |
| SCHEMBL20488157 | 0.72 | DDB1 (0.33) | — | |
| SCHEMBL12451455 | 0.71 | MGAM (0.32) | — | |
| SCHEMBL20488474 | 0.70 | CHRM1 (0.31) | — | |
| SCHEMBL31429136 | 0.70 | PTGS1 (0.44) | TRPA1LTB4RLTB4R2TSHRPTGS1 | |
| SCHEMBL25046725 | 0.70 | MGAM (0.31) | — | |
| Methyl Alcohol SCHEMBL8945240 | 0.69 | TRPA1 (0.48) | TRPA1LTB4RLTB4R2TSHRALDH1A1 | |
| Methyl Alcohol SCHEMBL8945244 | 0.69 | TRPA1 (0.48) | TRPA1LTB4RLTB4R2TSHRALDH1A1 | |
| Methyl Alcohol SCHEMBL8945235 | 0.69 | TRPA1 (0.48) | TRPA1LTB4RLTB4R2TSHRALDH1A1 | |
| SCHEMBL5131364 | 0.67 | PTGS1 (0.53) | TRPA1PTGS1PTGS2MT-CO1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | TRPA1 4885/4885LTB4R 4605/4885LTB4R2 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.